GB0024795D0 - Pyrazole derivatives for the treatment of viral diseases - Google Patents

Pyrazole derivatives for the treatment of viral diseases

Info

Publication number
GB0024795D0
GB0024795D0 GBGB0024795.7A GB0024795A GB0024795D0 GB 0024795 D0 GB0024795 D0 GB 0024795D0 GB 0024795 A GB0024795 A GB 0024795A GB 0024795 D0 GB0024795 D0 GB 0024795D0
Authority
GB
United Kingdom
Prior art keywords
treatment
viral diseases
pyrazole derivatives
pyrazole
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0024795.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to GBGB0024795.7A priority Critical patent/GB0024795D0/en
Publication of GB0024795D0 publication Critical patent/GB0024795D0/en
Priority to US09/956,656 priority patent/US6699887B2/en
Priority to CZ20031297A priority patent/CZ20031297A3/cs
Priority to RU2003112610/04A priority patent/RU2270832C2/ru
Priority to CNB018171710A priority patent/CN1191239C/zh
Priority to JP2002534293A priority patent/JP4015548B2/ja
Priority to PCT/EP2001/011474 priority patent/WO2002030907A1/en
Priority to EP01986680A priority patent/EP1326843A1/en
Priority to AU2002221651A priority patent/AU2002221651B2/en
Priority to YU27203A priority patent/YU27203A/sh
Priority to HR20030251A priority patent/HRP20030251A2/hr
Priority to KR10-2003-7004984A priority patent/KR100534158B1/ko
Priority to BR0114483-9A priority patent/BR0114483A/pt
Priority to AU2165102A priority patent/AU2165102A/xx
Priority to HU0302722A priority patent/HUP0302722A2/hu
Priority to HK04103975.9A priority patent/HK1061021B/xx
Priority to CA002423515A priority patent/CA2423515A1/en
Priority to IL15487501A priority patent/IL154875A0/xx
Priority to MXPA03003070A priority patent/MXPA03003070A/es
Priority to NZ524740A priority patent/NZ524740A/en
Priority to CNA2005100088329A priority patent/CN1680333A/zh
Priority to PL01362918A priority patent/PL362918A1/xx
Priority to ARP010104697A priority patent/AR030858A1/es
Priority to PE2001000993A priority patent/PE20020750A1/es
Priority to PA20018530301A priority patent/PA8530301A1/es
Priority to UY26956A priority patent/UY26956A1/es
Priority to GT200100201A priority patent/GT200100201A/es
Priority to ZA200302519A priority patent/ZA200302519B/en
Priority to MA27096A priority patent/MA26951A1/fr
Priority to EC2003004547A priority patent/ECSP034547A/es
Priority to NO20031615A priority patent/NO20031615L/no
Priority to US10/766,712 priority patent/US7183296B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0024795.7A 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases Ceased GB0024795D0 (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
GBGB0024795.7A GB0024795D0 (en) 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases
US09/956,656 US6699887B2 (en) 2000-10-10 2001-09-20 Anti-HIV pyrazole derivatives
PL01362918A PL362918A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
HU0302722A HUP0302722A2 (hu) 2000-10-10 2001-10-04 Pirazolszármazékok, vírusos betegségek kezelésére és a vegyületeket tartalmazó gyógyszerkészítmények, továbbá pirazolszármazékok alkalmazása gyógyszerkészítmények előállítására
IL15487501A IL154875A0 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
CNB018171710A CN1191239C (zh) 2000-10-10 2001-10-04 用于治疗病毒性疾病的吡唑衍生物
JP2002534293A JP4015548B2 (ja) 2000-10-10 2001-10-04 ウイルス性疾患の処置のためのピラゾール誘導体
PCT/EP2001/011474 WO2002030907A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
EP01986680A EP1326843A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
AU2002221651A AU2002221651B2 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
YU27203A YU27203A (sh) 2000-10-10 2001-10-04 Pirazol derivati za tretiranje virusnih oboljenja
HR20030251A HRP20030251A2 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
KR10-2003-7004984A KR100534158B1 (ko) 2000-10-10 2001-10-04 바이러스성 질환의 치료를 위한 피라졸 유도체
BR0114483-9A BR0114483A (pt) 2000-10-10 2001-10-04 Derivado de pirazol para tratamento de doenças viróticas
AU2165102A AU2165102A (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
CZ20031297A CZ20031297A3 (cs) 2000-10-10 2001-10-04 Pyrazolové deriváty pro léčbu virových onemocnění
HK04103975.9A HK1061021B (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
CA002423515A CA2423515A1 (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases
RU2003112610/04A RU2270832C2 (ru) 2000-10-10 2001-10-04 Производные пиразола для лечения вирусных заболеваний
MXPA03003070A MXPA03003070A (es) 2000-10-10 2001-10-04 Derivados de pirazol para tratamiento de enfermedades virales.
NZ524740A NZ524740A (en) 2000-10-10 2001-10-04 Pyrazole derivatives for the treatment of viral diseases mediated by the human immunodeficiency virus (HIV)
CNA2005100088329A CN1680333A (zh) 2000-10-10 2001-10-04 用于治疗病毒性疾病的吡唑衍生物
PE2001000993A PE20020750A1 (es) 2000-10-10 2001-10-05 Derivados de pirazol
ARP010104697A AR030858A1 (es) 2000-10-10 2001-10-05 DERIVADOS DE PIRAZOL PARA EL TRATAMIENTO DE ENFERMEDADES VíRICAS
PA20018530301A PA8530301A1 (es) 2000-10-10 2001-10-09 Derivados de pirazol para el tratamiento de enfermedades virales
UY26956A UY26956A1 (es) 2000-10-10 2001-10-09 Derivados del pirazol para el tratamiento de enfermedades virales
GT200100201A GT200100201A (es) 2000-10-10 2001-10-09 Derivados de pirazol para el tratamiento der enfermedades viricas.
ZA200302519A ZA200302519B (en) 2000-10-10 2003-03-31 Pyrazole derivatives for treatment of viral diseases.
MA27096A MA26951A1 (fr) 2000-10-10 2003-04-07 Derives de pyrazole pour le traitement de maladies virales
EC2003004547A ECSP034547A (es) 2000-10-10 2003-04-08 Derivados de pirazol para el tratamiento de enfermedades virales
NO20031615A NO20031615L (no) 2000-10-10 2003-04-09 Pyrazol-derivater for behandling av virus-sykdommer
US10/766,712 US7183296B2 (en) 2000-10-10 2004-01-27 Anti-HIV pyrazole derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0024795.7A GB0024795D0 (en) 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases

Publications (1)

Publication Number Publication Date
GB0024795D0 true GB0024795D0 (en) 2000-11-22

Family

ID=9900999

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0024795.7A Ceased GB0024795D0 (en) 2000-10-10 2000-10-10 Pyrazole derivatives for the treatment of viral diseases

Country Status (28)

Country Link
US (2) US6699887B2 (https=)
EP (1) EP1326843A1 (https=)
JP (1) JP4015548B2 (https=)
KR (1) KR100534158B1 (https=)
CN (2) CN1191239C (https=)
AR (1) AR030858A1 (https=)
AU (2) AU2002221651B2 (https=)
BR (1) BR0114483A (https=)
CA (1) CA2423515A1 (https=)
CZ (1) CZ20031297A3 (https=)
EC (1) ECSP034547A (https=)
GB (1) GB0024795D0 (https=)
GT (1) GT200100201A (https=)
HR (1) HRP20030251A2 (https=)
HU (1) HUP0302722A2 (https=)
IL (1) IL154875A0 (https=)
MA (1) MA26951A1 (https=)
MX (1) MXPA03003070A (https=)
NO (1) NO20031615L (https=)
NZ (1) NZ524740A (https=)
PA (1) PA8530301A1 (https=)
PE (1) PE20020750A1 (https=)
PL (1) PL362918A1 (https=)
RU (1) RU2270832C2 (https=)
UY (1) UY26956A1 (https=)
WO (1) WO2002030907A1 (https=)
YU (1) YU27203A (https=)
ZA (1) ZA200302519B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1335898B1 (en) * 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
GB0113524D0 (en) * 2001-06-04 2001-07-25 Hoffmann La Roche Pyrazole derivatives
JP2006504803A (ja) * 2002-09-26 2006-02-09 ファイザー・インク ピラゾール誘導体
EP1556381B1 (en) 2002-09-26 2008-02-20 Pfizer Limited Pyrazole amides for treating hiv infections
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
GB0223234D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
GB0223232D0 (en) * 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
TW200423930A (en) * 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
CN100469769C (zh) * 2003-03-24 2009-03-18 弗·哈夫曼-拉罗切有限公司 作为逆转录酶抑制剂的苄基-哒嗪酮
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
WO2006004040A1 (ja) * 2004-07-01 2006-01-12 Daiichi Asubio Pharma Co., Ltd. Ｐｄｅ７阻害作用を有するチエノピラゾール誘導体
US20070005049A1 (en) * 2005-06-30 2007-01-04 Comben Richard H Apparatus and Method of Treating Urinary Incontinence by Heating Urethra
CN101511812A (zh) * 2006-07-05 2009-08-19 辉瑞产品公司 作为细胞色素p450抑制剂的吡唑衍生物
RU2451676C2 (ru) 2006-08-16 2012-05-27 Ф.Хоффманн-Ля Рош Аг Ненуклеозидные ингибиторы обратной транскриптазы
GB0713479D0 (en) * 2007-07-11 2007-08-22 Syngenta Participations Ag Substituted aromatic heterocyclic compounds as fungicides
WO2009080534A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
GB0823000D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isothiazole and pyrazole derivatives with plant growth regulating properties
BRPI1008000A2 (pt) 2009-02-25 2016-02-23 Daiichi Sankyo Co Ltd composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto.
FR2951549B1 (fr) 2009-10-15 2013-08-23 Olivier Schussler Procede d'obtention de bioprotheses medicales implantables
TW201213334A (en) 2010-08-23 2012-04-01 Daiichi Sankyo Co Ltd Crystal forms of free form of tricyclic pyrazolopyrimidine derivative
EP2810945A1 (en) 2010-08-23 2014-12-10 Daiichi Sankyo Company, Limited Dihydrochloride salt of a tricyclic pyrazolopyrimidine derivative
WO2014074628A1 (en) * 2012-11-08 2014-05-15 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compounds for treating hiv and methods for using the compounds
US9925190B2 (en) 2015-02-16 2018-03-27 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecules targeting HIV-1 Nef
JP7301042B2 (ja) 2018-03-30 2023-06-30 住友化学株式会社 複素環化合物及びそれを含有する有害節足動物防除組成物
WO2020081856A1 (en) * 2018-10-18 2020-04-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of hiv-1 nef for the treatment of hiv disease
FR3121927B1 (fr) 2021-04-19 2023-03-31 Eiffage Genie Civil Terrassement Procédé d’inertage des boues d’excavation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015060A1 (fr) 1992-01-22 1993-08-05 Nissan Chemical Industries, Ltd. Derive de pyrazole substitue et bactericide agrohorticole
TW336932B (en) * 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
RU2130453C1 (ru) * 1992-12-17 1999-05-20 Пфайзер Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, способ лечения, промежуточный продукт
CZ284157B6 (cs) * 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
US6005109A (en) 1997-10-30 1999-12-21 Pflizer Inc. Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity
WO2006027423A1 (fr) * 2004-08-09 2006-03-16 Simag Developpement Dispositif de saisie comportant un capteur optique suivi d’un moyen de filtrage

Also Published As

Publication number Publication date
UY26956A1 (es) 2002-04-26
PA8530301A1 (es) 2002-07-30
IL154875A0 (en) 2003-10-31
PE20020750A1 (es) 2002-08-21
AU2002221651B2 (en) 2006-10-19
NO20031615D0 (no) 2003-04-09
HUP0302722A2 (hu) 2003-12-29
NO20031615L (no) 2003-05-23
CA2423515A1 (en) 2002-04-18
RU2270832C2 (ru) 2006-02-27
CN1191239C (zh) 2005-03-02
ECSP034547A (es) 2003-05-26
RU2003112610A (ru) 2005-02-20
PL362918A1 (en) 2004-11-02
US20030018197A1 (en) 2003-01-23
BR0114483A (pt) 2003-07-01
YU27203A (sh) 2006-05-25
NZ524740A (en) 2005-09-30
HRP20030251A2 (en) 2005-02-28
JP4015548B2 (ja) 2007-11-28
GT200100201A (es) 2002-05-23
CN1680333A (zh) 2005-10-12
WO2002030907A1 (en) 2002-04-18
JP2004511469A (ja) 2004-04-15
US20040192752A1 (en) 2004-09-30
AU2165102A (en) 2002-04-22
HK1061021A1 (en) 2004-09-03
CN1469865A (zh) 2004-01-21
MA26951A1 (fr) 2004-12-20
US7183296B2 (en) 2007-02-27
ZA200302519B (en) 2004-06-30
KR100534158B1 (ko) 2005-12-06
EP1326843A1 (en) 2003-07-16
CZ20031297A3 (cs) 2004-01-14
MXPA03003070A (es) 2003-07-14
AR030858A1 (es) 2003-09-03
KR20030046492A (ko) 2003-06-12
US6699887B2 (en) 2004-03-02

Similar Documents

Publication Publication Date Title
IL154875A0 (en) Pyrazole derivatives for the treatment of viral diseases
PL362711A1 (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases
IL150742A0 (en) Pyridopyrimidinone derivatives for the treatment of neurodegenerative disease
IL196301A0 (en) Medicament for the treatment of hapatitis c
EE200300497A (et) Pürasoolderivaadid HIV raviks
IL159344A0 (en) Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease
PL376454A1 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
IL192991A0 (en) Use of tetrahydrocarbazole derivatives for the manufacture of medicanents for treating gonadotropin-releasing hormone
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
AU3009801A (en) Combinations of medicaments for treating viral diseases
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
HUP0401600A3 (en) Process for the preparation of 14-hydroxymorphine derivatives
GB0004531D0 (en) The treatment of respiratory diseases
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
GB0028484D0 (en) Imidazolone derivatives for the treatment of viral diseases
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
IL151188A0 (en) Medicament for viral diseases
AU5611701A (en) Agent for the diagnosis and therapy of viral diseases
PT1698338E (pt) S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
AU2001262520A1 (en) Combined preparation for the treatment of neoplasic diseases
AU4453301A (en) Use of spirolaxin for the treatment of diseases associated with abnormal angiogenesis
AU1324002A (en) Treatment of demyelinating diseases
GB9926985D0 (en) Use of substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and-cyanamides for the treatment of diseases
HK1057753A (en) Morpholin-acetamide derivatives for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)